2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Other
2
Classical hematology
2
Conditions
Multiple Myeloma
5
Mucositis
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell
2
Febrile Neutropenia
2
Cytokine Release Syndrome
2
Burkitt Lymphoma
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Smoldering Multiple Myeloma
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Polycystic Ovary Syndrome
1
Pancreatic Neoplasms
1
Pancreatic Adenocarcinoma
1
Neurotoxicity Syndromes
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Inflammation
1
Hematologic Neoplasms
1
Early Stage Triple Negative ER Low Breast Cancer
1
Disease Progression
1
Cryopyrin-Associated Periodic Syndromes
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Arthritis, Rheumatoid
1
Interventions
Radiotherapy
9
Cisplatin
8
Fibroblast Growth Factor 7
6
Low-Level Light Therapy
5
angiotensin I (1-7)
4
Radiation
4
Injections
4
Propolis
3
Morphine
3
Methotrexate
3
Leucovorin
3
Drug Therapy
3
Cryotherapy
3
glucarpidase
2
aluminum hydroxide, magnesium hydroxide, drug combination
2
Xylitol
2
Water
2
Radiotherapy, Intensity-Modulated
2
RRx-001
2
Probiotics
2
Pentoxifylline
2
Mouthwashes
2
Melphalan
2
Lidocaine
2
Ketamine
2
Interleukin 1 Receptor Antagonist Protein
2
Honey
2
Glutamine
2
Gabapentin
2
Fluorouracil
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Mucositis
×
Interleukin 1 Receptor Antagonist Protein
×
Clear all
NCT03233776
2024-11-18
AFFECT-1
Radboud University Medical Center
Phase 2
Completed
9 enrolled
NCT04099901
2024-11-18
AFFECT-2
Radboud University Medical Center
Phase 2
Completed
88 enrolled